OOIR: Observatory of International Research

Papers

(The median citation count of Annals of the Rheumatic Diseases is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Response to: ‘Successful treatment of plasma exchange for refractory systemic juvenile idiopathic arthritis complicated with macrophage activation syndrome and severe lung disease’ by Sato et al	874
Repeated false-negative tests delayed diagnosis of COVID-19 in a case with granulomatosis with polyangiitis under maintenance therapy with rituximab and concomitant influenza pneumonia	532
Response to: ‘Treatment adherence behaviours in rheumatic diseases during pandemic COVID-19: a Latin American experience' by Pineda-Sic et al	531
Correspondence on ‘Jan Gösta Waldenström and rheumatology‘	519
Correspondence to ‘Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumat	384
Short duration antibiotic therapy for native joint arthritis caused by Neisseria infection?	306
Response to: ‘Correspondence on ‘What comes after the lockdown? Clustering of ANCA-associated vasculitis: single-centre observation of a spatiotemporal pattern’’ by Hocevar et al	296
Response to: ‘Correspondence on: irritable bowel syndrome symptoms in axial spondyloarthritis more common than among healthy controls: is it an overlooked comorbidity?' by Proft et al.	290
Response to: ‘Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors’ by Jovani et al	287
Response to: ‘Correspondence on ‘Variants in urate transporters, ADH1B, GCKR and MEPE genes associated with transition from asymptomatic hyperuricaemia to gout: results of the first gout versus asympt	285
Antibody response to SARS-CoV-2 in patients receiving glucocorticoids with or without tocilizumab for COVID-19-associated hyperinflammation	281
Response to: ‘Off-label use of tofacitinib: a potential treatment option for SAPHO syndrome’ by Xie et al	250
Neutralisation of circulating SARS-CoV-2 delta and omicron variants by convalescent plasma and SARS-CoV-2 hyperimmune intravenous human immunoglobulins for treatment of COVID-19	247
Exaggerated neutrophil extracellular trap formation in Kawasaki disease: a key phenomenon behind the outbreak in western countries?	229
Response to: ‘Correspondence on ‘Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis’’ by Yang et al	221
Dysregulation of immune checkpoint molecules as a characteristic of autoimmune congenital heart block	219
Correspondence on ‘Standardisation of myositis-specific antibodies: where are we today?’	215
Response to: ‘Anti-Ku antibodies: important points to consider’ by Mahler et al	213
Response to: ‘Correspondence to ‘Slope sign': a feature of large vessel vasculitis?' by Milchert et al	213
AB0441 IMPACT OF URICEMIA ON PSORIATIC ARTHRITIS, AND ON SAFETY AND CLINICAL RESPONSE TO UPADACITINIB AND ADALIMUMAB: POST-HOC ANALYSIS OF PHASE III STUDIES	203
POS0993 ELEVATED INTRACELLULAR IFN SIGNALING BY T AND B CELLS BUT UNALTERED B CELL DISTRIBUTION IS A CHARACTERISTIC OF ANTI-SSA POSITIVE ASYMPTOMATIC WOMEN AT-RISK FOR CONGENITAL HEART BLOCK	188
POS0532 DEUCRAVACITINIB, AN ORAL, ALLOSTERIC, TYROSINE KINASE 2 (TYK2) INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: PATIENT-REPORTED OUTCOMES IN A PHASE 2 TRIAL	186
OP0057 EVALUATION OF SYSTEMIC SCLEROSIS PRIMARY HEART INVOLVEMENT IN THE EUROPEAN SCLERODERMA TRIALS AND RESEARCH (EUSTAR) COHORT	184
POS0389 LOW INCIDENCE OF LATE-ONSET GCA DURING THE FIRST YEAR IN PATIENTS WITH POLYMYALGIA RHEUMATICA — AN IMAGING-BASED STUDY	179
AB0372 PAIN SYNDROME, PHYSICAL ACTIVITY AND QUALITY OF LIFE IN WOMEN WITH OSTEOARTHRITIS AND SARCOPENIA	178

POS1021 THE EFFECT OF CANNABIDIOL ON QUANTITATIVE SENSORY TESTING PARAMETERS IN PATIENTS WITH HAND OSTEOARTHRITIS AND PSORIATIC ARTHRITIS: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL	172
POS0916 DRUG SURVIVAL OF BIOLOGIC AND TARGETED SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC THERAPIES IN PATIENTS WITH INFLAMMATORY ARTHRITIS: DATA FROM FIVE COUNTRIES OF LATIN AMERICA	165
POS1430 WATCH OUT FOR THE INFLAMMATORY RESPONSE IN AUTOIMMUNE DISEASES WITH INTERSTITIAL PNEUMONIA. A RETROSPECTIVE STUDY	165
POS1035 FORCED VITAL CAPACITY TRAJECTORIES AND RISK OF LUNG TRANSPLANT AND ILD-RELATED MORTALITY AMONG PATIENTS WITH RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE	164
AB0503 SELF-REPORTED CLINICAL AND PSYCHOLOGICAL FACTORS ASSOCIATED WITH ADHERENCE: RESULTS FROM THE BRAGGSS COHORT	160
POS1478-HPR ANALYSIS OF MEDICATION USAGE AND MONTHLY COSTS IN HOSPITALIZED PATIENTS WITH RHEUMATIC DISEASES: A RETROSPECTIVE OBSERVATIONAL STUDY	154
AB0738 EXPRESSION AND ROLE OF THE LNCRNA RP11-184M15.1 IN THE MYELOID COMPARTMENT DURING INFLAMMATION	153
AB0183 CARDIAC EFFECTS OF THE ARTHRITIS/HEART FAILURE COMORBIDITY	143
AB1016 SERUM CXCL-13 LEVELS ARE ASSOCIATED WITH ACTIVE NEUROLOGICAL INVOLVEMENT IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS	141
AB1151 CIRCULATING CTHRC1 LEVELS ARE ASSOCIATED WITH DISEASE SEVERITY AND PREDICT SURVIVAL IN SYSTEMIC SCLEROSIS	140
AB1598-HPR MOTHERHOOD AND FAMILY PLANNING BELIEFS IN WOMEN WITH AUTOIMMUNE RHEUMATIC DISEASES	133
AB1028 EFFECT OF RENIN-ANGIOTENSIN-SYSTEM INHIBITORS ON RENAL REMISSION IN LUPUS NEPHRITIS: A REAL-WORLD STUDY	133
AB1649-PARE BARRIERS TO DIAGNOSIS, TREATMENT, AND CARE FOR IgG4-RELATED DISEASE: DATA FROM A LARGE COHORT OF ITALIAN PATIENTS	129
OP0120 EFFECTIVENESS AND COST-EFFECTIVENESS OF PATIENT-INITIATED FOLLOW-UP SUPPORTED BY ASYNCHRONOUS TELEMONITORING IN SPONDYLOARTHRITIS (TeleSpA-STUDY): A PRAGMATIC MULTICENTRE RANDOMISED CONTROLLED	127
AB0661 TOFACITINIB PLUS IGURATIMOD IN RHEUMATOID ARTHRITIS-RELATED PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE: 13 CASES FROM A SINGLE CENTRE IN CHINA	126
AB0462 ONE-YEAR RETENTION RATE OF IXEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS. DATA OF THE SPANISH BIOBADASER REGISTRY	120
AB0943 ASSESSING THE IMPACT OF SARCOPENIA IN AXIAL SPONDYLOARTHRITIS	119
AB0666 CYCLING VERSUS SWITCHING AFTER INEFFECTIVENESS OF FIRST TUMOR NECROSIS FACTOR INHIBITOR DURING FIRST YEAR OF THERAPY - DEMOGRAPHIC AND CLINICAL DIFFERENCES IN RHEUMATOID ARTHRITIS	115
AB0916 EFFECTIVENESS OF A PERSONALIZED PHYSICAL TRAINING PROGRAM ON DISEASE ACTIVITY AND AEROBIC CAPACITY IN axSpA: A RANDOMIZED CONTROLLED STUDY	112
AB1225 COMPARISON OF THE ACUTE EFFECTS OF INTRAVENOUS ILOPROST ON FINGER POWER DOPPLER ULTRASOUND IN SCLERODERMA PATIENTS IN TWO INFUSION 4 WEEKS APART	111
OP0251 DURATION OF CLINICALLY MEANINGFUL ANALGESIC RESPONSE TO INTRA-ARTICULAR MM-II, A NOVEL SUSPENSION OF LARGE, EMPTY, MULTILAMELLAR LIPOSOMES, IN PATIENTS WITH PAINFUL KNEE OSTEOARTHRITIS: ANALYSI	107
AB1258 EFFECTIVENESS OF DUPILUMAB ON REFRACTORY CHRONIC RHINOSINUSITIS WITH NASAL POLYPS IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS: A CLINICAL AND CYTOLOGICAL STUDY	106
OP0012 AN INVESTIGATION OF THE DIFFERENTIAL THERAPEUTIC EFFECTS OF ROMOSOZUMAB ON POSTMENOPAUSAL OSTEOPOROSIS PATIENTS WITH OR WITHOUT RHEUMATOID ARTHRITIS COMPLICATIONS: A CASE-CONTROL STUDY	106
AB0313 SECONDARY PREVENTION OF OSTEOPOROSIS: CLINICAL AND FUNCTIONAL PROFILE OF ELDERLY PATIENTS WITH HIP FRACTURE	105
AB0732 CELLULAR AND MOLECULAR HALLMARKS OF EARLY METHOTREXATE RESPONSE IN RA	105
AB1134 SERUM ADVANCED GLYCATION END-PRODUCTS AND THEIR SOLUBLE RECEPTOR AS POTENTIAL NEW BIOMARKERS IN SYSTEMIC LUPUS ERYTHEMATOSUS	104
POS0071 IMMUNOMODULATORY TREATMENT AND IMMUNE RESPONSES TO COVID-19 BOOSTER SHOTS IN PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES: RESULTS FROM THE COVID-19 VACCINE RESPONSE IN RHEUMATOLOGY PATIENTS (C	102
POS0648 EFFICACY AND SAFETY OF LOW OR HIGH DOSE METHOTREXATE IN COMBINATION WITH ADALIMUMAB IN PATIENTS WITH ELDERLY-ONSET RHEUMATOID ARTHRITIS: RESULTS FROM THE RANDOMISED, CONTROLLED MIRACLE TRIAL	101
POS1117 1-YEAR FOLLOW-UP OUTCOME OF DIFFERENT TREATMENT REGIMENS FOR LUPUS NEPHRITIS	99
POS0160-HPR IMPACT OF A SMARTPHONE DIGITAL THERAPEUTIC (DTx) APP WITH REAL-TIME FEEDBACK IN THE MANAGEMENT OF AXIAL SPONDYLOARTHRITIS (axSpA) THROUGH PHYSIOTHERAPY HOME-BASED EXERCISE PROGRAM: A PILOT	97
POS0283 DISEASE - CHARACTERISTIC CHANGES CAN ALREADY BE FOUND IN INDIVIDUALS AT RISK OF SJÖGREN’S SYNDROME – RESULTS OF THE preSStige STUDY	95
POS0344 PAROTID TRANSCRIPTOMIC NETWORKS ASSOCIATED WITH B CELL HYPERACTIVITY, AND VIRUS/IFN ACTIVITY ARE TARGETED BY LEFLUNOMIDE/HYDROXYCHLOROQUINE THERAPY IN SJÖGREN PATIENTS AND ARE CAPTURED BY A CI	94
AB0394 COMORBIDITIES IN 40.643 PSORIATIC ARTHRITIS PATIENTS ACCORDING TO GENDER: RESULTS FROM E.PULSE, THE NATIONWIDE HEALTH DATA	93
AB1126 REBAMIPIDE ATTENUATES RENAL MANIFESTATIONS VIA ANTIOXIDANT EFFECTS ON PODOCYTES IN AN ANIMAL MODEL FOR SYSTEMIC LUPUS ERYTHEMATOSUS	92
POS1001 INDUCED PLURIPOTENT STEM CELL-DERIVED MESENCHYMAL STEM CELLS ALLEVIATE SJÖGREN’S SYNDROME BY MODULATING THE MATURATION PROCESS OF SPLENIC B CELLS	91
AB1620-HPR CHANGE IN THE UTILITY OF ANTINUCLEAR ANTIBODIES (ANA) FOLLOWING THE IMPLEMENTATION OF ANALYTICAL REQUEST BASED ON PATIENT PROFILE	89
AB0160 THE USE OF IL-6 INHIBITORS IN PATIENTS WITH POLYMYALGIA RHEUMATICA RECEIVING GLUCOCORTICOID THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS	88
POS0743 OPTIMIZING REFERRAL TO RHEUMATOLOGY – A NEW STRATEGY TO PREVENT REFERRAL OF PATIENTS WITH LOW LIKELIHOOD OF AN INFLAMMATORY RHEUMATIC DISEASE	88
POS0234 IMPACT OF PROPHYLACTIC TRIMETHOPRIM-SULFAMETHOXAZOLE ON THE INCIDENCE OF SERIOUS INFECTION IN PATIENTS WITH ANCA ASSOCIATED VASCULITIS: A MULTICENTER COHORT STUDY	86
AB1272 MANAGING OF ANCA-ASSOCIATED VASCULITIS: ADHERENCE TO TREATMENT GUIDELINES AND EARLY MODIFICATIONS, ARE WE THERE YET?	86
POS0878 INFERTILITY AND THE CHANCE OF SUCCESSFUL ASSISTED REPRODUCTION TREATMENTS IN CHILDBEARING WOMEN WITH RHEUMATIC DISEASES	85
AB0073 ANTIBODY RESPONSE AND COVID-19 DISEASE AFTER SARS-CoV-2 VACCINATION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES RECEIVING BIOLOGICAL TREATMENT	84
POS0349 SINGLE OSTEOCLAST RESORPTION ANALYSIS REVEALS AN INCREASED INTRINSIC OSTEOCLAST ACTIVITY IN RA PATIENTS	83
POS0697 OPHTHALMIC MANIFESTATIONS IN TAKAYASU ARTERITIS PATIENTS: A CROSS-SECTIONAL MONOCENTRIC STUDY	82
POS1220 MODULATING INFLAMMATION IN AN ADVANCED 3D MODEL OF RHEUMATOID ARTHRITIS SYNOVIAL TISSUE INCORPORATING FIBROBLASTS, ENDOTHELIAL CELLS AND MACROPHAGES	80
POS1377 REFINING AUTOANTIBODY PROFILES IN PATIENTS WITH RHEUMATOID ARTHRITIS – A SCANDINAVIAN STUDY ON 6900 SAMPLES	79
AB1089 CORRELATION OF AUTOANTIBODIES AND PERICARDITIS IN SLE PATIENTS	79
AB1331 DIAGNOSTIC CAPABILITY OF ANESTHETIC INTRA-ARTICULAR INJECTIONS FOR FEMOROACETABULAR IMPINGEMENT	78
POS0714 MYOCARDITIS AND MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) IN PATIENTS WITH MELANOMA RECEIVING IMMUNE CHECKPOINT INHIBITORS	78
AB1349 CORRELATION OF CHRONIC INFLAMMATION MARKERS WITH ULTRASOUND SIGNS OF ATHEROSCLEROTIC HEART DISEASE AND BRACHIOCEPHALIC ARTERIES LESIONS IN RHEUMATOID ARTHRITIS	76

AB0795 Are patients with ankylosing spondylitis afraid of falling compared to healthy controls?: the role of balance and posture	76
AB1019 THE EFFECTS OF THREE DIFFERENT VITAMIN D3 SUPPLEMENTATION REGIMENS IN DEFICIENT SUBJECTS ON INFLAMMATORY CYTOKINES – A RANDOMISED OPEN-LABEL PARALLEL GROUPS STUDY	76
AB0928 CHARACTERISTICS OF AXIAL PSORIATIC ARTHRITIS PATIENTS WITH SYMMETRICAL AND ASYMMETRICAL SACROILIITIS	75
AB0311 RHEUMATOID ARTHRITIS AND OSTEOPOROSIS: FREQUENCY AND ASSOCIATED FACTORS	75
AB0777 Influence of TNF inhibitors on subclinical atherosclerosis in Spondyloarthritis patients	74
AB1025 TRABECULAR BONE SCORE IN PATIENTS WITH AXIAL-SPONDYLOARTHRITIS	74
AB1127 ANTIOSTEOPOROTIC TREATMENT AND COVID-19 RISK: IS THERE AN ASSOCIATION?	74
AB0345 THERAPEUTIC DRUG LEVELS TO ACHIEVE GOOD EULAR RESPONSE IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING ADALIMUMAB: RESULTS FROM THE BIOLOGICS IN RHEUMATOID ARTHRITIS GENETICS AND GENOMICS STUDY	73
AB1134 BIBLIOMETRIC NETWORK ANALYSIS ON TOCILIZUMAB TREATMENT FOR COVID-19 PATIENTS	73
POS1566-PARE BEYOND MEDICATION – SELF MANAGEMENT AS A COMPLEMENTARY APPROACH FOR TREATING RMDS	72
AB0878 Higher vitamin D serum level is associated with a better clinical response to bDMARDs in patients with axial spondyloarthritis.	72
POS0740 IMPACT OF TIME TO REMISSION, FLARES AND EXPOSURE TO IMMUNOSUPPRESSIVES ON THE DEVELOPMENT OF ADVANCED CHRONIC KIDNEY DISEASE (STAGE IV OR WORSE) IN LUPUS NEPHRITIS	71
POS1526-HPR WHICH FACTORS INFLUENCE PATIENTS' PREFERENCES FOR TELEHEALTH APPLICATIONS IN RHEUMATIC DISEASES? A QUALITATIVE STUDY	71
POS0959 IMPACT OF INITIATION OF TARGETED THERAPY ON THE USE OF ASSOCIATED TREATMENTS AND HEALTHCARE CONSUMPTION IN PSORIATIC ARTHRITIS: A COHORT STUDY OF 9,793 PATIENTS FROM THE FRENCH HEALTH INSURANC	70
POS0851 FREQUENCY OF METABOLIC SYNDROME AND ITS RELATIONSHIP WITH DISEASE CHARACTERISTICS IN PATIENTS WITH SYSTEMIC SCLEROSIS	70
OP0128 ADHERENCE TO MEDICATIONS DURING PREGNANCY IN SYSTEMIC AUTOIMMUNE DISEASE	70
AB1553-HPR BASELINE CHARACTERISTICS OF PATIENTS WITH SLE ACROSS 5 REGISTRIES – THE LUPUSNET FEDERATED DATA NETWORK	69
AB0251 CLINICAL FEATURES OF KOREAN PATIENTS WITH ANTI-SRP ANTIBODY-ASSOCIATED IMMUNE-MEDIATED NECROTIZING MYOPATHY	69
POS0115 EOSINOPHILIC GIANT CELL ARTERITIS: A DIFFERENT SUBSET OF DISEASE?	69
POS1107 IMMUNOGENICITY, REACTOGENICITY AND SAFETY OF 2 DOSES OF AN ADJUVANTED HERPES ZOSTER SUBUNIT VACCINE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A RANDOMIZED CLINICAL TRIAL	69
POS1216 NIEMANN-PICK PROTEINS TYPE C2 DRIVES PROINFLAMMATORY PROPERTIES OF FIBROBLAST-LIKE SYNOVIOCYTES IN RHEUMATOID ARTHRITIS THROUGH MEDIATING CHOLESTEROL METABOLIC REPROGRAMMING	69
POS0813 PREDICTORS OF RESPONSE TO bDMARDs AND tsDMARDs THERAPY: THE ROLE OF MUSCULOSKELETAL ULTRASOUND AND POTENTIAL NEW BIOMARKERS	68
AB1320 DOPPLER ULTRASOUND IN GIANT CELL ARTERITIS: WHICH TERRITORIES SHOULD WE EXPLORE? A RETROSPECTIVE ANALYSIS OF A SINGLE CENTER EXPERIENCE	68
AB0482 PREVALENCE AND SEVERITY OF MAFLD IN PSORIATIC DISEASE: ARE WE MISSING SOMETHING?	68
AB0529 JAK-INHIBITORS PROMOTE INSULIN SENSITIVITY AND ENHANCE IMMUNOSUPPRESSIVE EFFECT OF INSULIN ON CD4+ T CELLS OF PATIENTS WITH RHEUMATOID ARTHRITIS	67
AB1323 ALL WALES GCA AUDIT 2023-A QUALITY IMPROVEMENT INITIATIVE TO IMPROVE GCA CARE ACROSS WALES	67
POS1386 REGIONAL DIFFERENCES IN PATIENT DIAGNOSIS JOURNEY AND HEALTHCARE UTILIZATION. RESULTS FROM THE INTERNATIONAL MAP OF AXIAL SPONDYLOARTHRITIS (IMAS)	65
POS1108 SUBCLINICAL ATHEROSCLEROSIS IS ASSOCIATED WITH FUTURE CARDIOVASCULAR EVENTS IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS AT APPARENT LOW RISK FOR CARDIOVASCULAR DISEASE: A LONGITUDINAL PROSPECTIVE	65
POS1394 VITAMIN D SUPPLEMENTATION REDUCES IMMUNOGLOBULIN DEPOSITS IN THE BRAIN OF PRISTANE-INDUCED LUPUS MICE	65
AB1535 A PROFILE OF SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASE-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION (SARD-PAH) FROM WESTERN INDIA: A SINGLE CENTRE RETROSPECTIVE STUDY	65
AB0393 MUSCULOSKELETAL MANIFESTATIONS IN PATIENTS DIAGNOSED WITH MARFAN SYNDROME	64
AB0445 EVALUATION OF SUBCLINICAL BOWEL INFLAMMATION USING FAECAL CALPROTECTIN LEVEL IN PATIENTS WITH PSORIATIC ARTHRITIS AND PSORIASIS – A PILOT STUDY	63
POS0866 LARGE-VESSEL INVOLVEMENT IN ANCA-ASSOCIATED VASCULITIS: A MULTICENTER CASE-CONTROL STUDY	63
AB1050 ANALYSIS OF FACTORS INFLUENCING THE NUMBER OF CHILDREN OF FEMALE SLE PATIENTS BY PATIENT’S QUESTIONNAIRE	63
POS0449 GENE THERAPY WITH INTERFERENCE miRNAs AS A NEW ALTERNATIVE FOR DISCOID CUTANEOUS LUPUS (DLE)	61
POS0118-PARE THE RAIISE SCHOOL PACK FOR TEACHERS SUPPORTING CHILDREN AND YOUNG PEOPLE WITH INVISIBLE ILLNESSES IN SCHOOL: A MULTI-STAKEHOLDER CO-CREATION PROCESS	60
AB0102 DIFFERENTIAL EXPRESSION OF ORTHOLOGUE GENES INVOLVED IN GLYCINE AND PYRUVATE METABOLISM CHARACTERIZE THE GUT MICROBIOME META-TRANSCRIPTOME OF SUBJECTS WITH ASYMPTOMATIC HYPERURICEMIA AND GOUT	60
AB0255 DESCRIPTIVE ANALYSIS OF A COHORT OF PATIENTS WITH JUVENILE DERMATOMYOSITIS UNDER FOLLOW-UP IN THE ADULT RHEUMATOLOGY OFFICE	59
AB1233 ROLE OF HEMATOLOGICAL INDICES IN SYSTEMIC SCLEROSIS: USE AS A PREDICTOR OF SUBCLINICAL VASCULAR DAMAGE, CARDIOVASCULAR EVENTS AND DEATH	59
OP0214 ASSOCIATIONS OF REMNANT CHOLESTEROL WITH ALL-CAUSE AND CAUSE-SPECIFIC THROMBOTIC RISK IN INDIVIDUALS WITH ANTIPHOSPHOLIPID SYNDROME	59
POS0594 NEW INSIGHTS INTO EARLY AND ESTABLISHED RHEUMATOID ARTHRITIS SUBTYPES THROUGH SEROLOGIC BIOMARKER PROFILING – RESULTS FROM THE SCANDRA PROJECT	59
AB1419 CLINICAL ANALYSIS OF FOUR CASES OF PACHYDERMOPERIOSTOSIS	58
POS1248 DAMAGE IN SJÖGREN’S DISEASE: INSIGHTS FROM THE GIRRCS SJOGREN’S DISEASE COHORT	58
POS0307 CENTRAL SENSITIVITY SYNDROME AFFECTS THE TREATMENT SATISFACTION IN PATIENTS WITH RHEUMATOID ARTHRITIS	58
AB0085 PRE-EXPOSURE PROPHYLAXIS OF SARS-COV-2 INFECTION AND SEVERE COVID-19 WITH TIXAGEVIMAB AND CILGAVIMAB (EVUSHELD) IN RHEUMATOLOGIC PATIENTS TREATED WITH RITUXIMAB AT RISK OF SEVERE COVID-19: EFFI	58
POS0310 BARICITINIB MAY REDUCE CO-EXISTING FIBROMYALGIA IN PEOPLE WITH RHEUMATOID ARTHRITIS: AN ULTRA-HIGH RESOLUTION MRI BRAIN STUDY	57
AB0610 EARLY RHEUMATOID ARTHRITIS AND THYROID DYSFUNCTION: A 20-YEARS FOLLOW-UP STUDY IN BULGARIA	57
POS0385 ORAL SYSTEMIC ENZYME COMBINATION ALLEVIATES SYSTEMIC INFLAMMATION, CARTILAGE DEGRADATION, AND PAIN IN KNEE OSTEOARTHRITIS–A PROOF-OF-MECHANISM, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STU	57
AB0857 ASSOCIATIONS AMONG PATIENT EMPOWERMENT, PATIENT ENGAGEMENT, PATIENT ACTIVATION AND CLINICAL MANIFESTATIONS IN PRIMARY SJÖGREN’S SYNDROME	56
AB1732 PROFILE OF MULTISYSTEM INFLAMMATORY SYNDROME (MIS-C) IN INFANTS DURING THE SECOND WAVE OF SARS-CoV-2 PANDEMIC: AN OBSERVATIONAL CROSS-SECTIONAL STUDY	56
AB1294 EFFICACY AND SAFETY OF DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN THE TREATMENT OF TAKAYASU ARTERITIS	56
AB0068 LONG-TERM FOLLOW-UP OF PATIENTS WITH RHEUMATIC DISEASES AND SARS-CoV-2 INFECTION: DATA FROM THE SAR-COVID REGISTRY	56
AB0847 KIDNEY INVOLVEMENT AND PROGRESSION IN PATIENTS WITH SYSTEMIC SCLEROSIS AND ISOLATED SJÖGREN’S SYNDROME	55
AB1636-HPR SOCIAL MEDIA USE BY PHYSIOTHERAPISTS, OCCUPATIONAL THERAPISTS AND ALLIED HEALTHCARE PROFESSIONALS IN KAZAKHSTAN	55
AB1285 ACUTE BRACHIAL PLEXITIS IN GIANT CELL ARTERITIS A CASE REPORT AND SYSTEMATIC REVIEW OF THE LITERATURE	55
AB1412 IMAGING TECHNIQUES IN ASSESSING THE MUSCULAR STATUS OF PATIENTS WITH CORONARY HEART DISEASE	54
AB1365 SKELETAL METASTASES OF DIGESTIVE ORIGIN IN RHEUMATOLOGY: A DESCRIPTIVE STUDY OF 18 CASES	54
AB0294 VITAMIN D LEVEL AND LOCOMOTIVE FUNCTIONS IN WOMEN WITH RHEUMATOID ARTHRITIS	54
POS1537-HPR PERCEIVED BARRIERS AND FACILITATORS TO PHYSICAL ACTIVITY AND ITS ASSOCIATED FACTORS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS	54
AB0881 Guselkumab Provides Sustained Improvements in Health-Related Quality of Life in Patients With Active Psoriatic Arthritis Through 2 Years of DISCOVER-2	53
AB0526 ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS USING SF-36 SCALE	53
AB0273 IDENTIFICATION OF RED FLAGS FOR INTERSTITIAL LUNG DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS	53
POS1384 NON-INVASIVE IN VIVO METABOLIC PROFILING OF INFLAMMATION IN JOINTS AND ENTHESES BY OPTOACOUSTIC IMAGING	52
POS1338 CENTRAL SENSITIZATION AND RELATED FACTORS IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER	52
AB1040 ASSOCIATION OF Q141K POLYMORPHISM OF ABCG2 GENE WITH THE EFFECTIVENESS OF URATE-LOWERING THERAPY IN PATIENTS WITH GOUT (PILOT STUDY)	52
POS0946 THE COURSE OF BONE MINERAL DENSITY DURING 8 YEARS OF TREATMENT WITH TNF-α INHIBITORS IN PATIENTS WITH ANKYLOSING SPONDYLITIS	52
AB0347 TREATMENT RESPONSE WITH ABATACEPT PLUS METHOTREXATE TREATMENT FOR RHEUMATOID ARTHRITIS: REAL-WORLD EVIDENCE FROM THE UK	52
POS0619 CLINICAL AND SUBCLINICAL INTERSTITIAL LUNG DISEASE IN RHEUMATOID ARTHRITIS: ASSOCIATED FACTORS.	52
POS0405 INCREASED LEVELS OF CELLULAR ADHESION MOLECULES ARE LINKED TO THE PRESENCE OF INTERSTITIAL LUNG DISEASE IN PATIENTS WITH AUTOIMMUNE DISEASES	51
OP0015 PROINFLAMMATORY MONOCYTES AND MACROPHAGES IN SYNOVIAL FLUID AND BURSAL TISSUE OF PATIENTS WITH POLYMYALGIA RHEUMATICA: POTENT PRODUCERS OF IL-6 AND GM-CSF	51
AB0963 Frequency of sexual dysfunction in psoriatic arthritis, Santo Domingo, Dominican Republic	51
AB0245 PULMONARY INVOLVEMENT IN RHEUMATOID ARTHRITIS AND SECONDARY SJÖGREN SYNDROME	51
POS0061 INTERCEPTION OF THE DEVELOPMENT OF RHEUMATOID ARTHRITIS BY A 1-YEAR COURSE OF METHOTREXATE IN ACPA-NEGATIVE ARTHRALGIA PATIENTS AT INCREASED RISK FOR RHEUMATOID ARTHRITIS: 4 YEAR RESULTS OF TH	50
OP0252 FACTORS ASSOCIATED WITH SEVERE COVID-19 OUTCOMES IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHY: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE PHYSICIAN-REPORTED REGISTRY	50
POS0615 IS DMARD-FREE REMISSION IMPOSSIBLE FOR ALL RHEUMATOID ARTHRITIS PATIENTS OR ONLY FOR THOSE REQUIRING BIOLOGICALS?	49
AB0032 ASSESSMENT OF AUTONOMIC DYSFUNCTION AND ITS RELATIONS WITH CLINICAL PARAMETERS IN FAMILIAL MEDITERRANEAN FEVER (FMF)	49
OP0037 A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, PHASE 3 STUDY OF SHR0302, A SELECTIVE JANUS KINASE 1 INHIBITOR, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE	49
POS1258 STRATIFICATION OF SJÖGREN’S DISEASE, BASED ON SYMPTOMS, CLINICAL AND ROUTINE BIOLOGICAL DATA, IS SUPPORTED BY DISTINCT PATHOPHYSIOLOGICAL PATHWAYS	49
POS1477-HPR UNDERSTANDING TREATMENT UTILISATION IN INDIVIDUALS WITH OSTEOARTHRITIS AND METABOLIC MULTIMORBIDITY: A CROSS-SECTIONAL STUDY	49
POS0334 DAPIROLIZUMAB PEGOL IMPACTS IMPORTANT IMMUNOLOGIC PATHWAYS IN SYSTEMIC LUPUS ERYTHEMATOSUS: PHARMACODYNAMIC ANALYSIS OF B CELL AND TYPE I INTERFERON PATHWAYS FROM A PHASE 2B TRIAL	49

POS0341 DECONVOLUTION OF TRANSCRIPTOMICS CHANGES IN DEUCRAVACITINIB-TREATED SUBJECTS REVEALS NOVEL MECHANISTIC EFFECTS OF TYK2 INHIBITION IN LUPUS	49
POS0226 GRANULOMATOSIS WITH POLYANGIITIS AND COURSE OF PREGNANCY - RESULTS FROM THE NATIONWIDE PREGNANCY REGISTER REVNATUS	49
POS0005 BASELINE BIOMARKERS PREDICT BETTER RESPONSES TO DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, IN A PHASE 2 TRIAL IN PSORIATIC ARTHRITIS	48
OP0177 IMMUNOGENICITY INDUCED BY TWO AND THREE DOSES OF THE BNT162B2 mRNA VACCINE IN PATIENTS WITH AUTOIMMUNE INFLAMMATORY RHEUMATIC DISEASES AND IMMUNOCOMPETENT CONTROLS: A LONGITUDINAL MULTI-CENTER	48
AB1618-HPR ENHANCING HERPES ZOSTER VACCINATION AMONG ADULT RHEUMATOLOGY PATIENTS ON JAK INHIBITORS IN KUWAIT: ASSESSING CURRENT UPTAKE AND IDENTIFYING IMPROVEMENT OPPORTUNITIES - A QUALITY IMPROVEMENT	48
POS1087 THE RELATIONSHIP BETWEEN CHANGES IN PSORIATIC ARTHRITIS DISEASE ACTIVITY AND COMORBIDITIES IN PATIENTS TREATED WITH bDMARDs	48
POS0756 DETERMINANTS OF HEALTH-RELATED QUALITY OF LIFE (HR-QoL) ACROSS THE SPECTRUM OF SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES: RESULTS FROM THE LEAP COHORT	48
POS0755 SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF A SINGLE ORALLY ADMINISTERED DOSE OF ENPATORAN IN A PHASE I STUDY OF HEALTHY JAPANESE AND CAUCASIAN PARTICIPANTS	47
OP0055 THE COMPARISON OF EFFECTS OF TWO DIFFERENT EXERCISE PROGRAM ON FUNCTIONAL CAPASITY AND QUALITY OF LIFE IN PREGNANT WOMEN WITH LOW BACK PAIN	46
OP0208-HPR EFFECT OF AN 8-WEEK SPECIALIZED PHYSICAL THERAPY PROGRAM ON SEXUAL HEALTH IN FEMALE PATIENTS WITH SYSTEMIC SCLEROSIS AND IDIOPATHIC INFLAMMATORY MYOPATHIES: A PILOT STUDY	46
POS0846 MORTALITY OUTCOME OF ACUTE MYOCARDIAL INFRACTION IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES, A QUALITATIVE APPROACH ANALYSIS OF THE NATIONAL INPATIENT SAMPLE FROM 2016-2019	46
POS0400 MODULATION OF HUMAN EARLY B CELL DEVELOPMENT THROUGH TARGETED DEGRADATION OF IKAROS AND AIOLOS WITH IBERDOMIDE	46
POS0148 SPARCC, MASES, LEI AND MEI INDEXES CAPTURE DIFFERENT PATIENTS WITH ENTHESITIS IN AXIAL SPONDYLOARTHRITIS, PERIPHERAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS.	45
POS0790 18F-FLUORODEOXYGLUCOSE (FDG) PET-CT IMAGING OF SALIVARY GLANDS IN PRIMARY SJÖGREN'S SYNDROME AND ITS CORRELATION WITH ULTRASONOGRAPHIC SCORES AND SALIVARY FLOW RATE COMPARED TO HEALTHY CONTROL	45
POS0984 PREVALENCE OF axSpA IN PATIENTS TREATED FOR CHRONIC BACK PAIN IN CHIROPRACTIC CLINICS: THE OREGON CHIROPRACTIC AXIAL SPONDYLOARTHRITIS STUDY (ORCAS) – AN INTERIM ANALYSIS	45
POS0452 ABNORMALITY OF TYPE I INTERFERON SIGNALLING IN B CELLS IN PRIMARY SJÖGREN´S SYNDROME AND THE IMPACT ON LABORATORY AND CLINICAL FINDINGS	45
POS1066 DEVELOPMENT OF PHYSICAL AND MENTAL COMPONENT SUMMARY SCORES FROM PROMIS-29 INSTRUMENT IN PATIENTS WITH PSORIATIC ARTHRITIS	45
POS0730 A BETTER SELF-EFFICACY IS PREDICTIVE OF BETTER HEALTH-RELATED QUALITY OF LIFE (HRQoL) IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS. DATA FROM A LATIN AMERICAN MESTIZO COHORT	45
OP0132 PREVALENCE AND COMORBIDITIES OF RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE IN SPAIN: A RETROSPECTIVE ANALYSIS OF ELECTRONIC HEALTH RECORDS USING NATURAL LANGUAGE PROCESSING	44
OP0080 STAT3 DEGRADERS INHIBIT Th17 DEVELOPMENT AND CYTOKINE PRODUCTION RESULTING IN PROFOUND INHIBITION OF COLLAGEN-INDUCED AUTOIMMUNE MURINE ARTHRITIS	44
POS0113 THE PREDICTIVE VALUE OF HEALTH LITERACY ON DISEASE ACTIVITY AND MEDICATION USE OVER TIME IN RHEUMATOID ARTHRITIS PATIENTS.	44
AB0371 CLINICAL SIGNIFICANCE OF GALECTIN-3 IN PATIENTS WITH RHEUMATOID ARTHRITIS BEFORE THE APPOINTMENT AND AFTER 12 MONTHS OF TREATMENT WITH BIOLOGICAL DRUGS (PRELIMINARY DATA).	43
AB0240 CORRELATION BETWEEN KLOTHO LEVELS AND ANKLE-BRACHIAL INDEX IN FEMALE RHEUMATOID ARTHRITIS PATIENTS	43
POS0365 RELAPSES ARE COMMON ΙΝ SEVERE HEMATOLOGICAL SLE: REAL-LIFE EXPERIENCE FROM THE “ATTIKON” LUPUS COHORT	43
AB1439 IS THERE AN INCREASED PREVALENCE OF DIABETES MELLITUS IN THE AXIAL SPONDYLOARTHROPATHY PATIENT GROUP: A REVIEW FROM A UK TEACHING HOSPITAL SPONDYLOARTHROPATHY SERVICE	43
POS1540-HPR CENTRAL SENSITIZATION PLAYS A PROMINENT ROLE IN DISEASE ACTIVITY, FUNCTIONAL IMPAIRMENT AND QUALITY OF LIFE IN PATIENTS WITH SPONDYLOARTHRITIS.	43
POS0541 PREDICTORS OF REMISSION IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH UPADACITINIB OR ADALIMUMAB IN THE SELECT-COMPARE PHASE 3 STUDY: CLINICAL STATUS AT WEEK 12, BUT NOT STANDARD LABORATORY ME	43
AB0230 THE INFLUENCE OF THE PATIENT'S PSYCHOLOGICAL STATUS ON THE INFLAMMATORY ACTIVITY OF RHEUMATOID ARTHRITIS	43
AB1076 IS THERE AN ADDITIONAL IMPACT OF STIMULATING CD8+ LYMPHOCYTES TO DETECT LATENT TUBERCULOSIS IN PATIENTS WITH RHEUMATIC DISEASES?	43
AB0476 PREDICTIVE FACTORS FOR THE DEVELOPMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA	42
AB0362 NEUTROPHIL COUNT REDUCTION 1 MONTH AFTER INITIATING SARILUMAB AND BASELINE SERUM SOLUBLE gp130 LEVELS CAN INDEPENDENTLY PREDICT CLINICAL REMISSION WITHIN 3 MONTH IN RHEUMATOID ARTHRITIS PATIENT	42
AB1012 MANAGEMENT OF BREAST CANCER TREATMENT INDUCED BONE LOSS- RE-AUDIT	42
AB0764 Factors associated with remission after gradual decline of TNFi in spondyloarthritis	42
AB0229 ACHIEVING GLUCOCORTICOID FREE MIGHT DECREASE RISK FOR CLINICAL FRACTURES IN PATIENTS WITH RHEUMATOID ARTHRITIS - TEN-YEAR FINDINGS FROM THE TOMORROW STUDY	41
POS0718 SIROLIMUS MONOTHERAPY FOR THROMBOCYTOPENIA IN PRIMARY ANTIPHOSPHOLIPID SYNDROME: A PILOT STUDY FROM A TERTIARY REFERRAL CENTER	41
AB1133 MUSCULOSKELETAL MANIFESTATIONS AMONG PATIENTS WITH COVID-19 INFECTION	41
Correction: Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label randomised controlled ORAL Surveillance trial	41
AB1494 THE QUALITY OF REPORTING IN RANDOMIZED CONTROLLED TRIALS OF BALANCE EXERCISES IN TOTAL KNEE ARTHROPLASTY	41
AB1468 ALL-CAUSE MORTALITY IN PATIENTS WITH PALINDROMIC RHEUMATISM: A POPULATION-BASED COHORT STUDY	41
POS1198 VACCINATION AGAINST COVID-19 SHOULD BE ENCOURAGED IN PATIENTS WITH RHEUMATIC DISEASE, AS MOST PATIENTS DEVELOP A SEROLOGICAL RESPONSE AGAINST THE VACCINE AND VACCINATION REDUCES SELF-IMPOSED I	40
POS1248 URIC ACID AND COVID-19: PATTERN OF CHANGES AND ASSOCIATION WITH PROGNOSIS	40
POS1501-HPR ADDRESSING THE VOCATIONAL DEVELOPMENT OF YOUNG PEOPLE WITH LONG-TERM HEALTH CONDITIONS IN HEALTH CARE SETTINGS: A SYSTEMATIC REVIEW AND MIXED METHODS SYNTHESIS	40
POS1106 MEDIATORS OF THE EFFECT OF THERAPEUTIC EXERCISE ON PAIN AND FUNCTION IN PATIENTS WITH KNEE AND HIP OSTEOARTHRITIS; AN INDIVIDUAL PATIENT DATA MEDIATION STUDY FROM THE OA TRIAL BANK.	40
Dupilumab as a potential steroid-sparing treatment for IgG4-related disease	40
Time to treat the climate and nature crisis as one indivisible global health emergency	40
POS1270 COVID19 VACCINATION IN PATIENTS WITH AXIAL AND PERIPHERAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS: ADVERSE EVENTS AND IMPACT ON DISEASE ACTIVITY	40
OP0131 ANIFROLUMAB EFFECTS ON RASH AND ARTHRITIS IN PATIENTS WITH SLE AND IMPACT OF INTERFERON SIGNAL IN POOLED DATA FROM PHASE 3 TRIALS	40
OP0128 INTEGRATED LABORATORY ABNORMALITY PROFILES OF UPADACITINIB WITH UP TO 4.5 YEARS OF EXPOSURE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED IN THE SELECT PHASE 3 PROGRAM	39
POS0154-HPR FACTORS FACILITATING THE SELF- AND SHARED-MANAGEMENT OF JIA BY CHILDREN, YOUNG PEOPLE, THEIR FAMILIES, AND PROFESSIONALS INVOLVED IN THEIR CARE: A REALIST EVALUATION	39
OP0183 IDENTIFICATION OF A SUBGROUP OF PEOPLE WITH RHEUMATOID ARTHRITIS CHARACTERISED BY HIGH DISABILITY OVER 10 YEARS, DESPITE LOW INFLAMMATION: RESULTS FROM TWO EUROPEAN PROSPECTIVE COHORT STUDIES	39
POS0339 PREDICTORS OF DEATH IN PATIENTS DIAGNOSED WITH GIANT CELL ARTERITIS IN WESTERN NORWAY 1972-2012	39
OP0224 CONTINUOUS COMPOSITE MEASURES FOR ROUTINE CARE IN PSORIATIC ARTHRITIS: THRESHOLDS OF MEANING AND CLINICALLY IMPORTANT DIFFERENCE ESTIMATES FOR THE 3 AND 4 VAS SCALES FROM A UK MULTICENTRE STUDY	39
POS0236 COMPARISON OF WORK PRODUCTIVITY OUTCOMES BETWEEN CHRONIC BACK PAIN PATIENTS WITH AND WITHOUT A DIAGNOSIS OF AXIAL SPONDYLOARTHRITIS AFTER 2-YEAR PROTOCOLISED FOLLOW-UP: DATA FROM THE SPONDYLOA	38
OP0285 COVID-19 HOSPITALIZATIONS, ICU ADMISSION, AND DEATH AMONG PATIENTS WITH IMMUNE MEDIATED INFLAMMATORY DISEASES (IMID) – A POPULATION-BASED STUDY	38
POS0197 RESPONSIVENESS OF ULTRASOUND SYNOVITIS AND CLINICAL OUTCOMES IN PSORIATIC ARTHRITIS TREATED WITH SECUKINUMAB: DATA FROM THE ULTIMATE TRIAL	38
POS0141 ACTIVE SCREENING FOR GOUT IDENTIFIES A LARGER CARDIOVASCULAR POPULATION AT HIGH MORTALITY RISK	38
POS0218 TUMOR-NECROSIS FACTOR INHIBITORS IMPROVE AORTIC STIFFNESS IN PATIENTS WITH LONGSTANDING RHEUMATOID ARTHRITIS	37
POS0223 PATTERNS OF JANUS KINASE INHIBITOR CYCLING FOR THE MANAGEMENT OF RHEUMATOID ARTHRITIS IN REAL-WORLD CLINICAL PRACTICE: AN ANALYSIS OF THE OPAL DATASET	37
POS0031 THE PREVALENCE OF INFLAMMATORY BACK PAIN AND HLA-B27 IN A LARGE POPULATION-BASED COHORT IN THE NETHERLANDS	37
POS0217 PULSE WAVE VELOCITY ELEVATION ABOVE INDIVIDUAL REFERENCE VALUES AND AORTIC-BRACHIAL STIFFNESS MISMATCH AS EARLY MARKERS OF ARTERIAL STIFFNESS INCREASE IN PATIENTS WITH RHEUMATOID ARTHRITIS	37
POS0264 THE EMERGING ROLE OF MAGNETIC RESONANCE IMAGING IN INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS: EVIDENCE FOR ULTRA SHORT TE AND COMPRESSED SENSING VIBE ACQUISITIONS AS PROMISING TOOLS FOR	37
POS0171 UNDERESTIMATION OF THE FRACTURE RISK BY THE FRAX FORMULA IN CHRONIC GLUCOCORTICOID USERS: A 10-YEAR LONGITUDINAL VALIDATION STUDY	37
POS0158-HPR UNDERSTANDING NURSE-LED CARE IN EARLY RA: INTERVIEW STUDY WITH RHEUMATOLOGY NURSE SPECIALISTS	37
POS0284 CLINICAL AND MRI COMPARISON OF ECCENTRIC VERSUS CONCENTRIC REHABILITATION IN SYMPTOMATIC KNEE OSTEOARTHRITIS: A PROSPECTIVE RANDOMIZED STUDY	37
POS0640 EFFECTIVENESS AND SAFETY OF ORIGINAL AND BIOSIMILAR ETANERCEPT IN bDMARD-NAÏVE PATIENTS IN A REAL-WORLD COHORT OF PORTUGAL	36
POS0519 BONE MINERAL DENSITY, LEAN AND FAT MASS IN POSTMENOPAUSAL WOMEN WITH RHEUMATOID ARTHRITIS	36
POS0728 QRISK3 RELATION TO CAROTID PLAQUE IS HIGHER THAN THAT OF SCORE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS	36
POS0178 GENE SIGNATURE FINGERPRINTS DIVIDE SLE PATIENTS IN SUBGROUPS WITH COMPARABLE BIOLOGICAL DISEASE PROFILES: A MULTICENTRE LONGITUDINAL STUDY	36
POS0791 DOSE-DEPENDENT RELATIONSHIP BETWEEN HISTORY OF DENTAL CARIES AND INCREASED RISK OF NEWLY-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS: A NATIONWIDE POPULATION-BASED COHORT STUDY	35
POS0532 AveRAGE PREDNISOLONE DOSE OF ONLY 1 MG PER DAY WAS RISK FACTOR FOR CLINICAL FRACTURES IN PATIENTS WITH RHEUMATOID ARTHRITIS - NINE-YEAR FINDINGS OF THE TOMORROW STUDY	35
POS0599 DISEASE ACTIVITY IN PATIENTS WITH RA BY SEROSTATUS AND TREATMENT LINE, FOLLOWING TREATMENT WITH ABATACEPT: RESULTS FROM AN INTERNATIONAL OBSERVATIONAL STUDY	35
POS0739 DEVELOPMENT OF A CONCEPTUAL MODEL TO UNDERSTAND DISEASE BURDEN IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND LONG-TERM ORGAN DAMAGE	35
POS0530 HOW DOES MULTIMORBIDITY IMPACT ON THE DIRECT AND INDIRECT COSTS IN PATIENTS WITH RHEUMATOID ARTHRITIS?	35
POS1037 CORRELATION BETWEEN SKIN INVOLVEMENT, JOINT INVOLVEMENT AND ENTHESITIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: POST-HOC ANALYSIS OF EQUATOR/EQUATOR2	34
AB0655 RHEUMATOID ARTHRITIS ACTIVITY BEFORE AND AFTER COVID-19 LOCKDOWN PERIOD	34
POS1437 INTERSTITIAL ANCA-ASSOCIATED VASCULITIS ASSOCIATES WITH SEVERE KIDNEY INJURY INDEPENDENT OF GLOMERULONEPHRITIS	34
POS0355 ASSOCIATIONS BETWEEN HLA-DRB1 SHARED EPITOPES ALLELES AND ANTI-RA33 ANTIBODIES IN DIFFERENT SUBSETS OF RHEUMATOID ARTHRITIS IN MALAYSIAN POPULATION	34
POS1460 MAJOR SALIVARY GLAND ULTRASOUND AND ELASTOGRAPHY FOR ASSESSMENT OF DISEASE ACTIVITY IN PATIENTS OF PRIMARY SJÖGREN'S SYNDROME	34
POS0939 WHEN DO THE ACTIVE SACROILIITIS MRI FINDINGS LOSS IN ANKYLOSING SPONDYLITIS? A RETROSPECTIVE, CROSS-SECTIONAL, OBSERVATIONAL STUDY	33
POS1173 A SHORT DELAY IN ARTHRITIS CARE IS ASSOCIATED WITH HIGHER DISEASE ACTIVITY - LESSONS FROM THE CORONAVIRUS DISEASE 19 (COVID-19) PANDEMIC	33
POS1065 CIRCULATING ENDOTHELIAL CELLS AS A MARKER OF CARDIOVASCULAR DISEASES IN PATIENTS WITH PSORIATIC ARTHRITIS	33
POS0851 IDENTIFICATION OF HUB GENES AND PATHWAYS IN DERMATOMYOSITIS BY BIOINFORMATICS ANALYSIS	33
POS1019 INCONSISTENCY OF THE DEGREE OF CARDIOVASCULAR RISK WHEN ASSESSED USING DIFFERENT INDICES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS	33
POS1086 DIFFERENCES IN PROINFLAMMATORY AND LIPID PROFILE BETWEEN PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS AND RHEUMATOID ARTHRITIS	33
POS1160 BRUCELLAR SPONDYLODISCITIS: CLINICAL AND MAGNETIC RESONANCE IMAGING FINDINGS	33
POS1141 ASSESSING RELEVANT JOINTS FOR MONITORING CPPD DISEASE: A SYSTEMATIC LITERATURE REVIEW OF IMAGING TECHNIQUES BY THE OMERACT ULTRASOUND – CPPD SUBGROUP	33
POS1200 IL-6 HIGHER LEVEL AFTER TOCILIZUMAB TREATMENT AS A PREDICTOR OF NOT-SURVIVAL IN COVID19 SEVERE PNEUMONIA: THE EXPERIENCE OF THE COVIBAS-STUDY	33
POS1305 TREATMENT RESPONSE TO TUMOR NECROSIS FACTOR INHIBITORS IN ADULTS WITH JUVENILE IDIOPATHIC ARTHRITIS: DATA FROM THE NOR-DMARD STUDY	32
AB0040 PYRUVATE DEHYDROGENASE KINASES AS A POTENTIAL TARGET IN THE TREATMENT OF OSTEOARTHRITIS TO UNLEASH THE METABOLIC FLOW?	32
POS1289 CHRONIC LOW BACK PAIN: THERAPEUTIC STRATEGIES AND CLINICAL OUTCOMES IN A MILITARY POPULATION	32
POS1273 A CHANGE IN A REHABILITATION MODEL INCREASES WORK CAPACITY AT 36 MONTHS IN LOW BACK PAIN	32
POS1416 THE IMPACT OF NON-PERSISTENCE ON RESOURCE UTILIZATION COSTS IN IMMUNE-MEDIATED RHEUMATIC DISEASES	32
POS1438 EARLY FACTORS ASSOCIATED WITH THE INITIATION OF TREATMENT WITH BIOLOGICS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS – RESULTS FROM A SINGLE CENTRE RETROSPECTIVE COHORT STUDY	32
POS1468-HPR THE IMPACT OF COVID-19 ON RHEUMATOLOGY HEALTH CARE WORKERS AND THEIR SCIENTIFIC OUTPUT: HEAVY LIES THE CROWN ON FEMALE RHEUMATOLOGISTS	32
POS1333 ANKLE ARTHRITIS IN JUVENILE IDIOPATHIC ARTHRITIS: DON'T MISS TENOSYNOVITIS. CLINICAL AND SONOGRAPHIC FEATURES OF ANKLE TENOSYNOVITIS IN JIA	32